Negative Second PET‐CT 1 Year After Treatment of Oropharyngeal Cancer Predicts Low Mortality and Recurrence
Authors:
- 22 June 2025
- journal article
- Published by Wiley in Clinical Otolaryngology
- Vol. 50 (6) , 973-980
Abstract
Objective: To determine the prediction value of a second PET‐CT imaging study performed 1 year after treatment for patients with oropharyngeal carcinoma.Methods: A Retrospective single‐institution tertiary care centre study. Included are all patients diagnosed with oropharyngeal cancer between 2010 and 2020 at a tertiary medical centre. All 77 suitable patients completed at least two ET‐CT scans during the post‐treatment period, the first at 3 months and the second at 1 year. The follow‐up extended to 5 years after treatment. The main outcome measures were overall survival (OS) and disease‐free survival (DFS).Results: In total, 55 (65%) patients had no evidence of disease (NED) on the 1‐year PET‐CT. The negative predictive value of 1‐year PET‐CT was 91% for 4‐year DFS and 100% for 4‐year OS. Regression analysis of NED on the 1‐year PET‐CT correlated with 5‐year DFS (odds ratio [OR] 55, 95% confidence interval [CI] 5.2–500, p = 0.001) and low probability of 5‐year recurrence rates (OR 11.23, 1.23–100, p = 0.03).Conclusions: The findings of this study demonstrate that NED on PET‐CT performed 1 year after the completion of treatment for oropharyngeal cancer is indicative of very low recurrence rates and almost non‐existent mortality. We suggest performing a second PET‐CT study at 1 year post‐treatment on all patients with negative results on the first one performed at 3 months post‐treatment. Negative findings on the second study may allow for a more lenient clinical follow‐up protocol.Keywords
This publication has 18 references indexed in Scilit:
- PET Imaging of Oral Cavity and Oropharyngeal CancersPET Clinics, 2022
- Oropharyngeal Cancer Incidence and Mortality Trends in All 50 States in the US, 2001-2017JAMA Otolaryngology–Head & Neck Surgery, 2021
- Second-look PET-CT following an initial incomplete PET-CT response to (chemo)radiotherapy for head and neck squamous cell carcinomaEuropean Radiology, 2019
- Posttreatment surveillance PET/CT for HPV‐associated oropharyngeal cancerHead & Neck, 2018
- Is immunohistochemical evaluation of p16 in oropharyngeal cancer enough to predict the HPV positivity?Reports of Practical Oncology and Radiotherapy, 2017
- Oropharynx (p16—) and Hypopharynx2016
- HPV-Mediated (p16+) Oropharyngeal Cancer2016
- Predictive accuracy of first post‐treatment PET/CT in HPV‐related oropharyngeal squamous cell carcinomaThe Laryngoscope, 2014
- Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrenceCancer, 2012
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010